RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07553767, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Confirmed diagnosis of hepatitis B virus-related hepatocellular carcinoma (HCC) by pathology or contrast-enhanced CT/MRI.

    Inclusion criterion 2

    Underwent radical resection or local ablation therapy; CNLC (Chinese Liver Cancer Classification) stage Ia, Ib, or IIa; no residual tumor confirmed by imaging within 1-3 months postoperation.

    Inclusion criterion 3

  3. Child-Pugh score > 5 points.

    Exclusion criterion 5

  4. WBC < 3.5×10⁹/L or platelet count < 100×10⁹/L.

    Exclusion criterion 3

    ALT > 3×ULN or total bilirubin (TBIL) > 2×ULN.

    Exclusion criterion 4

  5. For women of childbearing potential: negative pregnancy test and effective contraception during treatment and for 24 weeks after the last dose.

    Inclusion criterion 7

    Pregnant or breastfeeding women.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07553767, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 to 65 years, male or female.
  • Confirmed diagnosis of hepatitis B virus-related hepatocellular carcinoma (HCC) by pathology or contrast-enhanced CT/MRI.
  • Underwent radical resection or local ablation therapy; CNLC (Chinese Liver Cancer Classification) stage Ia, Ib, or IIa; no residual tumor confirmed by imaging within 1-3 months postoperation.
  • HBsAg positive and HBsAg level < 2000 IU/mL.
  • No prior systemic chemotherapy, immunotherapy, or targeted therapy before enrollment.
  • Able to provide written informed consent and comply with the follow-up schedule.
  • For women of childbearing potential: negative pregnancy test and effective contraception during treatment and for 24 weeks after the last dose.

Exclusion Criteria:

  • Recurrent or metastatic HCC at enrollment.
  • Contraindication to peginterferon alfa-2b treatment.
  • WBC < 3.5×10⁹/L or platelet count < 100×10⁹/L.
  • ALT > 3×ULN or total bilirubin (TBIL) > 2×ULN.
  • Child-Pugh score > 5 points.
  • INR > 1.5.
  • History of organ transplantation or planned transplantation.
  • Hypersensitivity to peginterferon alfa-2b or any excipient of the study drug.
  • Pregnant or breastfeeding women.
  • Participation in another interventional clinical trial.
  • History of significant alcoholism or drug abuse.
  • Genetic or metabolic liver disease (Wilson disease, hemochromatosis, etc.).
  • Coinfection with HAV, HCV, HEV, EBV, CMV , or other viral hepatitis that may interfere with study evaluation.
  • Unable to comply with study procedures and follow-up.
  • Other conditions deemed inappropriate by the investigator.

Quoted from ClinicalTrials.gov, NCT07553767, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07553767, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07553767